Mannose
ApprovedSmall molecule
Mannose is one of 53 small molecule programs targeting Recurrent urinary tract infections. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
364 competitors in Growth
#DrugCompanyPhaseTrials
1Mannose
UUniversity of Colorado, Denver
Approved
Genotropin
EMD SeronoPreclinical
Lenvima
EisaiPreclinical
Aricept
EisaiPreclinical
Zolymbus
AbbViePreclinical
Zyloprim
Alnylam PharmaceuticalsPreclinical
Somavaratan
Novo NordiskPreclinical
Herceptin
OOrganon and Co
Preclinical
Glucophage
EMD SeronoPreclinical
EGRIFTA WR
TTheratechnologies
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mannose. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Colorado, Denver